Prohibits substitution of prescribed epilepsy drugs by pharmacists without prior notification to and written consent of physician and patient.
Impact
If enacted, A2020 will significantly amend the existing protocols related to the dispensing of anti-epileptic medications. By mandating that both parties—the prescribing physician and the patient—must give documented consent before any drug substitution can occur, the law aims to reduce the potential risks associated with the variability in drug formulations. As different anti-epileptic drugs can have diverse effects on individual patients, this policy is designed to mitigate the risk of adverse reactions that might result from simply switching to an equally rated drug without proper evaluation and agreement.
Summary
Assembly Bill A2020 seeks to enact stringent regulations concerning the substitution of anti-epileptic drugs. Specifically, the bill prohibits pharmacists from interchanging any brand or generic anti-epileptic medication prescribed for the treatment of seizures without prior notification and written consent from both the prescribing physician and the patient, or the patient's legal guardian in applicable cases. The intent behind this legislation is to safeguard patients who experience seizures, ensuring that they receive the precise medications dictated by their healthcare providers.
Contention
The proposed legislation has the potential to ignite debate among healthcare professionals, particularly pharmacists and doctors. While proponents argue that obtaining informed consent is crucial for ensuring patient safety and proper management of epilepsy, critics may raise concerns about the practicality of enforcing such a requirement in a hospital or pharmacy setting. Additionally, some may argue that this could hinder patient access to quick and necessary adjustments in their treatment, particularly in urgent situations where immediate changes might be required due to adverse effects or lack of efficacy of current medications.
Carry Over
Prohibits substitution of prescribed epilepsy drugs by pharmacists without prior notification to and written consent of physician and patient.
A bill for an act relating to school personnel training, emergency care planning, authorizations for assisting, and limitations of liability concerning students with epilepsy or a seizure disorder.(See HF 835.)
A bill for an act relating to school personnel training, emergency care planning, authorizations for assisting, and limitations of liability concerning students with epilepsy or a seizure disorder.(See SF 368.)
A bill for an act relating to school personnel training, including by implementing provisions related to emergency care planning, authorizations for assisting, and limitations of liability concerning students with epilepsy or seizure disorder, and requiring the department of education to convene a health care-related training for school personnel work group. (Formerly HF 102.) Effective date: 07/01/2025.